The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

被引:0
|
作者
Lu Chen
Jingjuan Huang
Weihua Wu
Shengjun Ta
Xiaoyi Xie
机构
[1] Shanghai Chest Hospital,Department of Ultrasound
[2] Shanghai Jiao Tong University,Department of Cardiology
[3] Shanghai Chest Hospital,Department of Ultrasound
[4] Shanghai Jiao Tong University,undefined
[5] Yan’an People’s Hospital,undefined
关键词
Right ventricle; Strain; Chemoradiotherapy; Non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (− 28.3 ± 4.6% vs. − 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (− 23.4 ± 2.9% vs. − 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202–1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.
引用
收藏
页码:1009 / 1017
页数:8
相关论文
共 50 条
  • [41] Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
    Tang, Shi
    Cong, Xiaofeng
    Zheng, Dan
    Chen, Chen
    Liu, Zengguang
    Gao, Jie
    Zhang, Huimin
    Zhang, Youhao
    Liu, Ziling
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer
    Katsui, Kuniaki
    Ogata, Takeshi
    Watanabe, Kenta
    Yoshio, Kotaro
    Kuroda, Masahiro
    Hiraki, Takao
    Kiura, Katsuyuki
    Maeda, Yoshinobu
    Toyooka, Shinichi
    Kanazawa, Susumu
    ACTA MEDICA OKAYAMA, 2021, 75 (03) : 269 - 277
  • [43] Clinical Outcomes of Concurrent Chemoradiotherapy Versus Radiotherapy Alone in the Elderly Patients with Stage III Non-Small Cell Lung Cancer
    Kim, D. Y.
    Song, C.
    Kim, S. H.
    Kim, Y. J.
    Lee, J. S.
    Kim, J. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E514 - E514
  • [44] EFFICACY AND SAFETY OF CONCURRENT CHEMORADIOTHERAPY IN ELDERLY PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE STUDY
    Boku, Shogen
    Kasamatsu, Yu
    Yoshinoya, Kiyokazu
    Kida, Takashi
    Izumi, Hiroyuki
    Ushijima, Yo
    Kasamatsu, Yoshihiro
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S487 - S487
  • [45] Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium
    Walraven, I.
    Damhuis, R. A.
    ten Berge, M. G.
    Rosskamp, M.
    van Eycken, L.
    de Ruysscher, D.
    Belderbos, J. S. A.
    CLINICAL ONCOLOGY, 2017, 29 (11) : E177 - E185
  • [46] Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)
    Socinski, Mark A.
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Gray, Jhanelle E.
    Park, Keunchil
    Vincent, Mark
    Mann, Helen
    Newton, Michael
    Dennis, Phillip A.
    Antonia, Scott J.
    CLINICAL LUNG CANCER, 2021, 22 (06) : 549 - 561
  • [47] Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) - a German radiation oncology survey
    Kaesmann, Lukas
    Eze, Chukwuka
    Taugner, Julian
    Roengvoraphoj, Olarn
    Belka, Claus
    Manapov, Farkhad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [48] A retrospective analysis of lymphopenia rates during and after sequential and concurrent radical chemoradiotherapy for patients with stage III non-small cell lung cancer (NSCLC)
    Westley, R.
    Philipps, L.
    Lock, I.
    Ahmed, M.
    Mcdonald, F.
    LUNG CANCER, 2019, 127 : S80 - S80
  • [49] Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?
    Chalmers, Anna W.
    Patel, Shiven B.
    Akerley, Wallace
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1198 - 1200
  • [50] Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity
    Phernambucq, E. C. J.
    Spoelstra, F. O. B.
    Verbakel, W. F. A. R.
    Postmus, P. E.
    Melissant, C. F.
    van den Brink, K. I. Maassen
    Frings, V.
    van de Ven, P. M.
    Smit, E. F.
    Senan, S.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 132 - 138